STAB OTC
Statera Biopharma, Inc.
1W: -99.0%
1M: -99.5%
3M: -99.0%
YTD: -99.7%
1Y: -99.0%
3Y: -99.9%
$0.00
+0.00 (+0.00%)
Weekly Expected Move ±54.3%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships0
As Filer
counterparties named
4
As Counterparty
mentioned by others
2022-11-03
Earliest Filing
2025-07-25
Latest Filing
Mentioned As Counterparty
4 mentionsOther companies that named STAB in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| TIVC Tivic Health Systems, Inc. | partner | Licensor of TLR5 agonist programs Entolimod and Entolasta | 2025-07-25 | View |
| TIVC Tivic Health Systems, Inc. | partner | Licensor of TLR5 agonist programs Entolimod and Entolasta | 2025-06-25 | View |
| TIVC Tivic Health Systems, Inc. | partner | Partnered with Tivic Health Systems, Inc. to grant an exclusive worldwide license for Entolimod and Entolasta and sold s | 2025-02-12 | View |
| COEPW Coeptis Therapeutics Holdings, Inc. | partner | Clinical stage biopharmaceutical company with whom Coeptis entered into a binding Letter of Intent for STAT-201. | 2022-11-03 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR